CLINICAL PRESENTATIONS

 


Final 30-day results of the DEFLECT III trial: 
A prospective randomised evaluation of the novel embolic protection DEFLECTion device during TAVI

Andreas Baumbach, Bristol Heart Institute, University Hospitals Bristol, UK
For the Deflect Study Group: J Schofer, D Tchetche, P Stella, C Pietras, H Parise, K Abrams, J Forrest, M Cleman, J Reinöhl, T Cuisset, D Blackman, G Bolotin, S Spitzer, U Kappert, M Gilard, T Modine, D Hildick-Smith, M Haude, P Margolis, A Brickman, S Voros and A Lansky

The presentation can be found below in PDF format.
Final 30-day results of the DEFLECT III trial: a prospective randomised evaluation of the novel embolic protection DEFLECTion device during TAVI


TAVR Accessory Devices
How Much Clinical Trial Rigor and What Are the Appropriate Surrogate Endpoints
Alexandra Lansky, MD
The presentation can be found below in PDF format.

TAVR Accessory Devices - Clinical Trial Rigor and Appropriate Surrogate Endpoints


Significant Lesion Volume Reduction 

Final Results of the DEFLECT I Trial 
Cerebral Protection Devices - The Keystone Heart Deflector Device

Alexandra Lansky, MD

The presentation can be found below in PDF format.

Final Results of the DEFLECT I Trial - TCT 2013



The First Report of the DEFLECT I Trial: 

A Prospective, Single Arm Feasibility Study to Evaluate the Safety and Performance of the KeyStone Heart TriGuardTM Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)
The presentation can be found below in PDF format.

First Report DEFLECT-I Study - EuroPCR 2013

The results were presented  at EuroPCR 2013 during the Hot-Line - First-in-man in Valvular Heart Disease session
by M.Mullen MD in Paris, France - May 22, 2013



Novel Maximum Coverage Embolic Protection Device for Use in TAVI
The presentation can be found below in PDF format.

Embolic Protection Device for Use in TAVI - EuroPCR 2013

Presented at EuroPCR 2013 by A.Lansky MD during:
Interventions for Structural Heart Disease ⋅ Topic: Stroke
Incidence and Prevention of Cerebrovascular Events after TAVI

Angiographic imaging results of a novel cerebral protection device: anchorage matters
Angiographic imaging results of a novel cerebral protection device: anchorage matters - EuroPCR 2013

Presented at EuroPCR 2013 by S.Meller  during:
Interventions for Structural Heart Disease ⋅ Topic: Stroke

The TriGuard Cerebral Protection Device is not commercially available in the USA.